Pharma Is NOT One Sector—a fact that many investors overlook when evaluating pharmaceutical companies. Although businesses in the pharmaceutical industry are often grouped under a single sector, they operate using very different business models. Some focus on manufacturing generic medicines, while others specialize in vaccines, contract research, biologics, animal healthcare, or complex drug formulations.
Understanding these differences is essential because every business model has its own growth drivers, profit margins, regulatory requirements, and risks. Looking beyond the “pharma” label can help investors make more informed decisions and avoid comparing companies that operate in entirely different segments.
Why Understanding Pharma Business Models Matters
The pharmaceutical industry is one of the most diverse sectors in the market. Companies may manufacture medicines, develop new drugs, produce active pharmaceutical ingredients (APIs), provide contract manufacturing services, or focus on veterinary healthcare.
As a result, two pharmaceutical companies can have completely different revenue sources, customer bases, and long-term growth prospects.
Instead of evaluating every pharma company using the same criteria, investors should first understand what business the company is actually engaged in.
1. Aurobindo Pharma – Global Generics and Specialty Medicines
Aurobindo Pharma is one of India’s largest pharmaceutical exporters with operations across more than 150 countries.
Its business is built around large-scale manufacturing and exports, making it a major player in global healthcare markets.
Core Business Areas
- Generic medicines
- Active Pharmaceutical Ingredients (APIs)
- Injectable medicines
- Specialty pharmaceuticals
Growth Drivers
- Rising demand for affordable generic medicines
- Expansion into regulated international markets
- Product portfolio diversification
- Global healthcare demand
Since export markets contribute significantly to revenue, regulatory approvals and international compliance remain critical factors for future growth.
2. Granules India – High-Volume Pharmaceutical Manufacturing
Granules India follows a completely different approach.
Rather than focusing on highly specialized therapies, the company concentrates on manufacturing widely used medicines at large scale with cost-efficient production.
Core Business Areas
- High-volume manufacturing
- Cost leadership
- Everyday pharmaceutical products
Common medicines include:
- Paracetamol
- Ibuprofen
- Metformin
Competitive Advantage
Its ability to manufacture large quantities efficiently helps improve operational margins while serving both domestic and export markets.
3. Shilpa Medicare – Complex and Specialty Pharmaceuticals
Shilpa Medicare focuses on specialized pharmaceutical products where technical expertise creates higher barriers to entry.
Unlike mass-market manufacturers, the company operates in complex therapeutic areas.
Core Business Areas
- Oncology medicines
- Biologics
- Specialty injectables
- Complex formulations
Why It Stands Out
These products generally require advanced manufacturing capabilities and strict regulatory approvals, making competition relatively limited.
4. Gland Pharma – Sterile Injectables and CDMO
Gland Pharma has established itself as a leading manufacturer of sterile injectable medicines.
In addition, it operates as a Contract Development and Manufacturing Organization (CDMO), partnering with global pharmaceutical companies.
Core Business Areas
- Sterile injectables
- CDMO services
- International exports
Growth Opportunities
- Growing outsourcing demand
- Expansion in regulated markets
- Increasing healthcare spending globally
Quality standards and regulatory compliance are particularly important for companies operating in this segment.
5. NGL Fine-Chem – Veterinary Healthcare Specialist
Unlike traditional pharmaceutical companies serving human healthcare, NGL Fine-Chem focuses primarily on animal healthcare.
Core Business Areas
- Veterinary APIs
- Animal healthcare products
- Livestock healthcare
- Pet care solutions
Growth Drivers
Global demand for better livestock productivity and rising pet healthcare expenditure continue to support long-term opportunities in this niche segment.
6. Viyash Life Sciences – Integrated Pharmaceutical Platform
Viyash Life Sciences operates across multiple parts of the pharmaceutical value chain.
Instead of relying on a single business segment, the company maintains a diversified operating model.
Core Business Areas
- APIs
- Finished formulations
- CDMO services
- Companion animal healthcare
Competitive Advantage
Diversification across businesses reduces dependence on any single revenue stream while creating multiple growth opportunities.
7. IOL Chemicals & Pharmaceuticals – Bulk Drug Manufacturer
IOL Chemicals is well known for manufacturing Ibuprofen APIs and other bulk pharmaceutical ingredients.
The company is also gradually expanding into finished formulations.
Core Business Areas
- Bulk drug manufacturing
- API production
- Formulations
Business Strength
Its expertise in large-scale API production supports pharmaceutical manufacturers both in India and overseas.
8. Zydus Lifesciences – Diversified Healthcare Company
Zydus Lifesciences is among India’s most diversified healthcare companies.
Its operations span multiple pharmaceutical categories, making it less dependent on any single business segment.
Core Business Areas
- Generic medicines
- Vaccines
- Biosimilars
- Specialty medicines
- Pharmaceutical research
Long-Term Growth Drivers
- Innovation
- Research capabilities
- Expanding product pipeline
- International presence
Its diversified business model helps balance opportunities across different healthcare segments.
9. Marksans Pharma – OTC Healthcare Products
Marksans Pharma primarily operates in the Over-the-Counter (OTC) medicine segment.
Rather than focusing only on prescription medicines, the company serves consumer healthcare markets.
Core Business Areas
- OTC medicines
- Consumer wellness products
- International markets
Geographic Presence
The company has established a strong footprint in markets such as:
- United Kingdom
- Australia
Growing demand for self-medication and wellness products continues to support this business model.
10. Suven Life Sciences – CRDMO and Drug Discovery
Suven Life Sciences differs significantly from traditional pharmaceutical manufacturers.
Instead of selling medicines directly, the company partners with global pharmaceutical firms by providing research and development services.
Core Business Areas
- Contract Research, Development and Manufacturing (CRDMO)
- Drug discovery
- Pharmaceutical research
- Innovation partnerships
Why This Segment Is Growing
As global pharmaceutical companies increasingly outsource research activities, CRDMO businesses continue to benefit from rising demand.
Different Business Models, Different Investment Opportunities
Although all these companies belong to the pharmaceutical industry, they should not be evaluated in the same way.
Some focus on:
- Generic medicine exports
- API manufacturing
- Contract manufacturing (CDMO)
- Contract research (CRDMO)
- Oncology medicines
- Vaccines
- Biosimilars
- Veterinary healthcare
- Consumer healthcare products
Each segment operates under different market dynamics, regulatory environments, and competitive pressures.
Therefore, comparing two pharma companies solely based on sector classification can lead to incorrect investment conclusions.
Key Factors Investors Should Evaluate
Before investing in any pharmaceutical company, consider the following:
Business Model
Understand exactly how the company generates revenue.
Product Portfolio
Evaluate whether products are diversified or concentrated in one category.
Regulatory Compliance
Companies serving regulated markets face stricter approval processes.
Research and Development
Innovation can become a significant long-term competitive advantage.
Export Presence
International markets often contribute substantially to revenue for Indian pharmaceutical companies.
Financial Performance
Review revenue growth, profitability, debt levels, and cash flows before making investment decisions.
Final Thoughts
Pharma Is NOT One Sector because the industry consists of multiple specialized business models serving different markets and customers. A company manufacturing generic medicines operates very differently from one engaged in biologics, vaccines, veterinary healthcare, contract manufacturing, or pharmaceutical research.
For investors, understanding these distinctions is far more valuable than simply identifying a company as a “pharma stock.” A well-informed investment decision should consider the company’s business model, revenue sources, product mix, competitive strengths, and long-term growth strategy rather than relying only on sector classification.
Ultimately, successful investing in the pharmaceutical industry is about identifying quality businesses whose operations align with your investment objectives, risk tolerance, and long-term financial goals.
Disclaimer: This article is intended for educational purposes only and should not be considered investment advice. Investors should conduct their own research or consult a qualified financial advisor before making any investment decisions.
Total Users : 11216